Douglas Cliff
As the year draws to a close, Wall Street is set to crown Eli Lilly (NYSE:LLY) among the best in Big Pharma, while Novo Nordisk (NVO), its closest rival in the lucrative obesity drug market, falls behind amid
Eli Lilly to end 2024 among best in Big Pharma; Novo among worst
